Drugs / lesogaberan
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00863161 | Mar 2009 → Feb 2010 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00757419 | Sep → Dec 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00688402 | Apr → Jun 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00684190 | Mar → Jun 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT02818309 | Jan 2015 → Nov 2017 | gastroesophageal reflux disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01043185 | Dec 2009 → May 2010 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01005251 | Oct 2009 → Jul 2010 | dyspepsia, gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00703534 | May 2008 → Jan 2009 | dyspepsia, gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00743444 | Feb 2007 → Feb 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00394472 | Nov 2006 → Jun 2007 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lesogaberan | “The γ-aminobutyric acid type B-receptor agonist lesogaberan (AZD3355) has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite proton...” PMID 25407279 ↗ Nov 2014 |
| Known as | AZD3355 | “Lesogaberan (AZD3355) is a novel γ-aminobutyric acid B-type receptor agonist designed to treat gastro-oesophageal reflux disease (GERD) by inhibiting transient lower...” PMID 22730470 ↗ Jun 2012 |
| Action | Activate | “a novel gamma-aminobutyric acid type B receptor agonist” PMID 20451523 ↗ May 2010 |
| Modality | Small molecule | — CHEMBL448343 ↗ |
| Route | Oral | “150 mg bid, oral, 7 days” NCT00684190 ↗ |
| Target | GABBR1 | “GABA-B receptor 1 agonist” CHEMBL448343 ↗ |
| Target | GABBR2 | “GABA-B receptor 2 agonist” CHEMBL448343 ↗ |